Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers

@article{Coutinho2008PulmonaryBP,
  title={Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers},
  author={Henrique Douglas Melo Coutinho and Vivyanne dos Santos Falc{\~a}o-Silva and Greg{\'o}rio Fernandes Gonçalves},
  journal={International Archives of Medicine},
  year={2008},
  volume={1},
  pages={24 - 24}
}
Cystic fibrosis is the most common and best known genetic disease involving a defect in transepithelial Cl- transport by mutations in the CF gene on chromosome 7, which codes for the cystic fibrosis transmembrane conductance regulator protein (CFTR). The most serious symptoms are observed in the lungs, augmenting the risk of bacterial infection. The objective of this review was to describe the bacterial pathogens colonizing patients with cystic fibrosis. A systematic search was conducted using… 
Targeting Lung Inflammation in Cystic Fibrosis
TLDR
The underlying mechanisms that cause neutrophils to lose their function for pathogen clearance are not well understood; therefore, effective pharmacological approaches are lacking.
Environmental Pseudomonas are a source of Novel Antibiotics that inhibit Cystic fibrosis derived pathogenic Pseudomonas aeruginosa
TLDR
It is hypothesized that environmental Pseudomonas from diverse soil and water habitats produce secondary metabolites capable of inhibiting the growth of CF derived P. aeruginosa, which is an opportunistic human pathogen evolving resistance to many currently used antibiotics.
[Analysis of the frequency of isolation and drug resistance of microorganisms isolated from the airways of adult CF patients treated in the Institute of Tuberculosis and Lung Disease during 2008-2011].
TLDR
The analysis of microbiological materials from adult CF patients treated in IGiChP allowed the determination of the prevalence of potentially pathogenic microorganisms and the antimicrobial resistance of the most frequently isolated bacteria.
Cystic fibrosis lung environment and Pseudomonas aeruginosa infection
TLDR
The deterministic alterations in lung physiology as a result of CF and the impact of those changes on the microbiota are revisited, with special emphasis on P. aeruginosa and the influence of other non-genetic factors on CF.
Role of neutrophils in cystic fibrosis lung disease
TLDR
Cystic fibrosis is a genetic syndrome caused by mutations in the CF Transmembrane Conductance Regulator gene, and neutrophil responses are now investigated as outcomes of the aetiological therapies in CF, such as hypertonic saline, antiproteases, CFTR correctors and potentiators.
Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs—A Review
TLDR
The most common changes undergone by P. aeruginosa at each stage of infection development in CF lungs are reviewed to help to design more effective antimicrobial treatments and to identify new targets for future drugs to prevent the progression of infection to chronic stages.
Differentiation of pulmonary bacterial pathogens in cystic fibrosis by volatile metabolites emitted by their in vitro cultures: Pseudomonas aeruginosa, Staphylococcus aureus, Stenotrophomonas maltophilia and the Burkholderia cepacia complex.
TLDR
Multivariate statistical analysis reveals that the four taxa can be well discriminated by the differences in the headspace VOC concentration profiles, and the compounds that should be targeted in breath as potential biomarkers of airway infection were identified.
Using Small-Molecule Adjuvants to Repurpose Azithromycin for Use against Pseudomonas aeruginosa.
TLDR
A novel approach to combatting pseudomonal infections through the use of bis-2-aminoimidazole adjuvants that can potentiate the activity of a macrolide antibiotic commonly prescribed to CF patients as an anti-inflammatory agent is described.
A study of the diagnosis, treatment and epidemiology of Mycobacterium abscessus in patients with cystic fibrosis
TLDR
RGM is a novel culture medium, which can be embedded alongside routine culture for other CF pathogens without any requirement for decontamination, and means that all respiratory samples submitted from patients with CF can be conveniently cultured for NTM, considerably improving the service offered to clinicians and patients.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 91 REFERENCES
Laboratory Aspects of Management of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
TLDR
The state of the art in the laboratory diagnosis of the infectious agents associated with CF lung disease is discussed and misidentification of seemingly harmless saprophytes as B. cepacia complex organisms may have profound consequences for the patient.
Lung Infections Associated with Cystic Fibrosis
TLDR
As the modalities of CF research have changed over the decades from empirical histological studies to include biophysical measurements of CFTR function, the clinical management of this disease has similarly evolved to effectively address the ever-changing spectrum of CF-related infectious diseases.
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.
TLDR
A consensus statement on regular maintenance treatment, or treatment on demand, was given and different routes of administration of antibiotics were recommended for different clinical situations, and the design of future antibiotic studies in the context of Pseudomonas aeruginosa lung infection in cystic fibrosis patients were recommended.
Pathophysiology and management of pulmonary infections in cystic fibrosis.
TLDR
This comprehensive State of the Art review summarizes the current published knowledge base regarding the pathophysiology and microbiology of pulmonary disease in cystic fibrosis and potential future therapies.
Dynamics of bacterial colonisation in the respiratory tract of patients with cystic fibrosis.
  • N. Renders, H. Verbrugh, A. van Belkum
  • Biology, Medicine
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  • 2001
Infection Control in Cystic Fibrosis
TLDR
A consensus conference to craft recommendations for infection control practices for CF care providers was sponsored, and it will be critical to measure the dissemination, implementation, and potential impact of these guidelines to monitor changes in practice and reduction in infections.
Isolation of Infectious Cystic Fibrosis Patients: Results of a Systematic Review
TLDR
A systematic literature review of segregation of CF patients colonized with Burkholderia cepacia species, Pandoraea species, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, or Alcaligenes species found recommendations to be separated from noncolonized patients in single rooms.
Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients
TLDR
The reduced prevalence of P. aeruginosa over the last decade has been associated with a concurrent reduction of infections by Bcc and, as compared to other centers in Italy, Europe, and the US, with a low incidence of emerging pathogens such as S. maltophilia and A. xylosoxidans.
Antimicrobial Peptide Therapeutics for Cystic Fibrosis
TLDR
Small bioactive peptides have the potential to attack two of the components responsible for the progression of lung damage in the CF disease: infection and inflammation.
Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis.
...
1
2
3
4
5
...